Tvardi Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
TVRD$1.410.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Year Ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Operating expenses: · · · · · | ||||||
| Research and development | | $18,011 | | $23,650 | ||
| General and administrative | | 8,737 | | 4,457 | ||
| Total operating expenses | | 26,748 | | 28,107 | ||
| Loss from operations | | (26,748) | | (28,107) | ||
| Interest income | | 1,375 | | 747 | ||
| Other income (expense), net | | 7,159 | | (2,037) | ||
| Net loss | | $(18,214) | | $(29,397) | ||
| | | | | | | |
| Net loss per share attributable to common stockholders: | | | | | | |
| Basic | | $(2.46) | | $(11.42) | ||
| Diluted | | $(3.26) | | $(11.42) | ||
| Weighted-average common shares outstanding: | | | | | | |
| Basic | | | 7,419,060 | | | 2,574,233 |
| Diluted | | | 7,783,182 | | | 2,574,233 |
| | | | | | | |
| Comprehensive loss: | | | | | | |
| Net loss | | $(18,214) | | $(29,397) | ||
| Unrealized gain on short-term investments | | | 8 | | | — |
| Comprehensive loss | | $(18,206) | | $(29,397) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.